Kala Pharmaceuticals has submitted a new drug application to the FDA for Inveltys, its inflammation and pain treatment candidate for those who have undergone ocular surgery, according to a company press release.
Inveltys (KPI-121 1%) is a twice-a-day topical ocular corticosteroid that utilizes the company’s proprietary mucus penetrating particle (MPP) technology, selectively sized nanoparticles with coatings that enhance drug penetration and distribution in ocular tissues, the release said.
Two phase 3 clinical trials, in which Inveltys achieved statistical significance over placebo in
Uncategorized